E-intervention on Subclinical Fear of Cancer Recurrence
Launched by THE UNIVERSITY OF HONG KONG · Jan 12, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new online program designed to help cancer survivors manage their fears about cancer coming back. It's called eConquerFear-HK, and it’s based on a method that helps people think about their worries in a healthier way. The trial is specifically looking at how well this program works for Chinese cancer survivors who are feeling anxious about their cancer returning, but who don’t have severe anxiety.
To participate, you need to be a Cantonese- or Mandarin-speaking survivor of colorectal or breast cancer who has recently completed surgery and any follow-up treatments, like chemotherapy or radiotherapy, within the last six months. Participants should also have mild to moderate fears about cancer recurrence, as measured by a questionnaire. If you join the trial, you can expect to use the online program and provide feedback on your experience. It’s a great opportunity to receive support and help others while contributing to valuable research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cantonese- or Mandarin-speaking Chinese cancer survivors
- • recently diagnosed with potentially curable (stage 0 to III) colorectal or breast cancer
- • had recently completed surgery as primary treatment
- • have completed hospital-based adjuvant treatments (including radiotherapy and chemotherapy) within the past six months
- • scored 13 to 21 on the fear of cancer recurrence-short form will be recruited.
- Exclusion Criteria:
- • non-Chinese ethnicity
- • metastatic cancer
- • with current diagnosis of depression or psychosis or are currently receiving psychological treatments
- • language or intellectual difficulties that prevent them from understanding the intervention content
- • having limited or no Internet access.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Danielle Ng, PhD
Principal Investigator
School of Public Health, The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported